<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and treatment of comorbid conditions in patients undergoing electroconvulsive therapy (ECT)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and treatment of comorbid conditions in patients undergoing electroconvulsive therapy (ECT)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Evaluation and treatment of comorbid conditions in patients undergoing electroconvulsive therapy (ECT)</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Condition</td> <td class="subtitle1">Management</td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Aortic stenosis</td> <td>Echocardiography should be performed to assess severity if not done within the past year or if there is a change in symptoms. If stenosis is severe, then consult cardiologist before proceeding with ECT.</td> <td>Limited data suggest that ECT is safe with the use of short-acting intravenous beta-blockers to minimize procedure-related hypertension and tachycardia.<sup>[1]</sup></td> </tr> <tr> <td>Asthma or chronic obstructive pulmonary disease</td> <td>Discontinue theophylline by tapering the dose, if possible. Continue outpatient regimen of bronchodilators and inhaled glucocorticoids. Provide standard treatment during an asthma exacerbation (inhaled beta-agonists and, if necessary, glucocorticoids, before proceeding with ECT).</td> <td>Theophylline increases the risk of status epilepticus after ECT.<sup>[2]</sup></td> </tr> <tr> <td>Atrial fibrillation</td> <td>Continue outpatient medications for control of heart rate. Control heart rate with calcium-channel blockers if needed. Manage anticoagulation as described below.</td> <td>ECT appears to be safe in patients with atrial fibrillation. Patients may have conversion to and from sinus rhythm during ECT. The effect of spontaneous rate conversion on embolization rates is unknown.</td> </tr> <tr> <td>Coronary artery disease (stable)</td> <td>Continue medications such as aspirin, statins, antihypertensive agents, and antianginal medications, including nitrates for chronic cardiac conditions. Continue aspirin and clopidogrel in patients with coronary stents.</td> <td>Discontinuation of long-term cardiac medications on the morning of the procedure increases the risk of cardiac ischemia.</td> </tr> <tr> <td>Diabetes</td> <td>Measure blood glucose levels before and after ECT treatment. If breakfast is likely only delayed, patients may delay taking their usual morning insulin until after ECT and before eating. If ECT happens later in the morning, where breakfast and lunch are likely to be missed, then give one-half the usual total morning dose as intermediate-acting insulin. Withhold oral agents and short-acting insulin until patient can eat. Perform ECT early in the morning if possible.</td> <td>The effect of ECT on blood glucose is unpredictable because of changes in diet, appetite, and energy level that may result from ECT. Individual ECT treatments raise blood glucose levels in patients with diabetes to the same degree as in patients without diabetes.</td> </tr> <tr> <td>Hypertension (poorly controlled)</td> <td>Start or intensify antihypertensive medications; delay ECT until blood pressure is &lt;140/90 mmHg. Avoid beta-blockers.</td> <td rowspan="2">Blood pressure increases during the postictal phase of ECT. Beta-blockers may shorten the seizure duration and reduce the efficacy of ECT.<sup>[3]</sup></td> </tr> <tr> <td>Hypertension (well-controlled)</td> <td>Continue usual antihypertensive medication(s).</td> </tr> <tr> <td>Implantable cardioverter-defibrillator (ICD)</td> <td>Turn off detection mode of ICD during ECT. Perform continuous electrocardiographic monitoring throughout treatment. Place resuscitative equipment by the patient's bedside in the event that external defibrillation is necessary. Make sure that ICD has been interrogated routinely.</td> <td>ECT appears to be safe in patients with an ICD.<sup>[4]</sup></td> </tr> <tr> <td>Implanted pacemaker</td> <td>A magnet should be available at the patient's bedside in the event that electrical interference leads to pacemaker inhibition and bradycardia.</td> <td>In rare cases, postprocedural supraventricular tachycardia can occur.<sup>[4]</sup></td> </tr> <tr> <td>Need for long-term anticoagulation</td> <td>Continue anticoagulation to maintain an international normalized ratio of up to 3.5, unless there is an increased risk of intracranial hemorrhage (eg, intracranial mass or aneurysm).</td> <td>ECT appears to be safe in patients who require long-term anticoagulation.<sup>[5]</sup></td> </tr> <tr> <td>Pregnancy</td> <td>The informed-consent and risk-stratification process should include an obstetrician and an anesthesiologist. In addition to standard monitoring of the patient, noninvasive fetal monitoring should be used after 14 to 16 weeks. After 24 weeks, a nonstress test with a tocometer should be performed before and after treatments.</td> <td>Pregnancy would require modification of the anesthetic technique, positioning of the patient, and monitoring requirements.</td> </tr> </tbody></table></div><div class="graphic_reference">Sources:<br/><ol>
<li>Mueller PS, Barnes RD, Varghese R, et al. The safety of electroconvulsive therapy in patients with severe aortic stenosis. Mayo Clin Proc 2007; 82:1360.</li>
<li>Devanand DP, Decina P, Sackeim HA, Prudic J. Status epilepticus following ECT in patient receiving theophylline. J Clin Psychopharmacol 1988; 8:153.</li>
<li>Rumi DO, Solimene MC, Takada JY, et al. Electrocardiographic and blood pressure alterations during electroconvulsive therapy in young adults. Arg Bras Cardiol 2002; 79:149.</li>
<li>Dolenc TJ, Barnes RD, Hayes DL, Rasmussen KG. Electroconvulsive therapy in patients with cardiac pacemakers and implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2004; 27:1257.</li>
<li>Mehta V, Meuller PS, Gonzalez-Arriaza HL, et al. Safety of electroconvulsive therapy in patients receiving long-term warfarin therapy. Mayo Clin Proc 2004; 79:1396.</li>
</ol></div><div id="graphicVersion">Graphic 55652 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
